Lixivaptan BALANCE study is a 650-patient Phase III, global, multi-center, randomized, placebo-controlled, double-blind, study of lixivaptan for hyponatremia in patients with heart failure. The primary objective is to evaluate the safety and effectiveness of lixivaptan, when compared to the placebo, in increasing serum sodium from baseline in heart failure patients with hyponatremia. In previous studies, lixivaptan improved blood sodium levels, lowered body weight and increased urine volume. Those studies suggest that lixivaptan may play an important role in treating hyponatremia and the signs and symptoms of water retention associated with heart failure, Syndrome of Inappropriate Anti-Diuretic Hormone(SIADH), and Liver Cirrhosis with
Serum (blood) form of immunotherapy. Blood serum and plasma are some of the largest sources of biomarkers, whether for diagnostics or therapeutics. Its vast dynamic range, further complicated by the presence of lipids, salts, and post-translational modifications, as well multiple mechanisms of degradation, presents challenges in analytical reproducibility, sensitivity, resolution, and potential efficacy. For analysis of biomarkers in blood serum samples, it is possible to do a pre-separation by free-flow electrophoresis that usually consists of a depletion of serum albumin protein. This method enables greater penetration of the proteome via separation of a wide variety of charged or chargeable analytes, ranging from